AKT (inhibitor)

Class

AKT kinase inhibitor

Notes

original target text: AKT inhibitor

AKT, also called protein kinase B, is an intracellular enzyme that sits at the center of the PI3K/AKT/mTOR signaling pathway, one of the most frequently activated growth and survival circuits in human cells. When growth factors bind receptors on the cell surface, a chain of signaling events activates AKT, which then turns on programs that promote cell growth, proliferation, and resistance to programmed cell death, while suppressing processes that would normally limit unchecked division. In many cancers, mutations or amplifications in upstream components of this pathway, such as PI3K itself or the tumor suppressor PTEN, or in AKT itself, lead to constant pathway activity, giving tumor cells a persistent survival and growth advantage independent of external signals. Small-molecule AKT inhibitors are designed to block this enzyme's kinase activity, aiming to shut down the abnormal signaling and push cancer cells back toward death or growth arrest. Because the same pathway also governs normal cell metabolism and tissue maintenance, AKT inhibition is relevant across a range of solid tumors and blood cancers where pathway activation is common, and it is often considered alongside other agents that target different nodes of the same signaling network. This class-wide rationale explains why AKT inhibitors appear across multiple cancer types rather than a single disease.